Drug Trial Radar · NCT07254481
VB19055 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population
Last checked: Nov 19, 2026Latest source record: Nov 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
86
Planned (sponsor's estimate)
Start
Oct 5, 2025
Primary completion
Jul 2026
Study completion Jul 2026
Sponsor
- Lead sponsor
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety,tolerability,pharmacokinetics and pharmacodynamics of VB19055 in the healthy Chinese population.
Conditions
- Hypertension
Interventions
VB19055Drug
In this part, VB19055 tablets will be administered as a single or multiple oral dose.
VB19055 placeboDrug
In this part, VB19055 placebo tablets will be administered as a single or multiple oral dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment emergent Adverse Events as assessed by CTCAE v5.0Time frame: Average half a month
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hangzhou First People's Hospital
Hangzhou, China · Recruiting
Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.